Trial Profile
Clinical characteristics and outcomes of a diverse cohort of patients with Multidrug-Resistant Gram-Negative Bacterial Infections infections treated with Ceftazidime-Avibactam
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Gram-negative infections
- Focus Therapeutic Use
- 18 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018